Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
Inflammatory bowel disease (IBD) patients with Crohn ’s disease and ulcerative colitis have been considered at increased risk of severe coronavirus disease 2019 (COVID-19) because they are often treated with immunosuppressive medications. Indeed, steroids and thiopurines in combination therapy with tumor necrosis factor (TNF) antagonists, but not TN F antagonist monotherapy, have been associated with a risk of severe COVID-19 in IBD patients.1,2 Expert consensus advocates that IBD patients should be vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Source: Gastroenterology - Category: Gastroenterology Authors: Serre-Yu Wong, Rebekah Dixon, Vicky Martinez Pazos, Sacha Gnjatic, Jean-Frederic Colombel, Ken Cadwell, ICARUS-IBD Working Group Tags: Brief Communication Source Type: research
More News: Coronavirus | COVID-19 | Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Respiratory Medicine | SARS | Ulcerative Colitis | Vaccines